On March 5th, Danish time, Novo Nordisk announced that its widely used semaglutide injection has made positive progress in treating kidney disease in a double-blind trial called FLOW. Compared with the placebo group, the patients with type 2 diabetes who received Smeaglutide (1.0mg) injection had a 24% reduction in renal disease progression, cardiovascular disease and renal death, reaching the primary end point of the trial.